Medicina y Especialidades Médicas
Departamento
Eli Lilly and Company
Indianapolis, EE. UU.
Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (2)
2025
- Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in RET Fusion-Positive NSCLC
JTO Clinical and Research Reports, Vol. 6, Núm. 7
2023
- Current heart failure disease management and treatment in accredited units from cardiology and internal medicine in Spain
Revista Clinica Espanola, Vol. 223, Núm. 7, pp. 405-413
